Researchers have developed a tobacco plant-based vaccine for patients with a chronic form of lymphoma, a specific type of cancer.

According to the first human study of the approach, researchers found that the vaccine could trigger an immune response in the body, which could lead to personalized vaccines that may kick start the patients' immune systems to attack the cancer

A vaccine aimed at reducing brain plaque didn't help cure Alzheimer's disease, researchers have found. The results of the five-year study disappointed scientists who believed that cutting down plaque levels in the brain would help reduce the symptoms of Alzheimer's.

The new research, led by Clive Holmes of Moorgreen Hospital in Southampton, looked at 80 patients with mild to moderate dementia. Researchers used amyloid-beta peptide on patients' brains to clear the plaque but results indicated that it didn't help patients live longer or slow the disease's progression

A human trial of a large-scale experimental AIDS vaccine has been cancelled following advice by a top scientist that it was unlikely to give useful results, the National Institutes of Health (NIH) said Thursday.

The vaccine trial, similar to a failed Merck and Co. product, was developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Disease. In a study called PAVE 100, the agency planned to include 2,400 men in the United States

A measles outbreak affecting 120 people in 15 states has alarmed health officials as it's the largest outbreak to happen in the last 10 years, according to the Centers for Disease Control and Prevention.

U.S. health authorities believe that the measles outbreak is related to travelers coming back to the United States from other countries

Approval of GlaxoSmithKline PLC's cervical cancer vaccine Cervarix is expected to be delayed further after the drug maker decided to submit additional data to the U.S. Food and Drug Administration.

Glaxo decided that it will add results from an ongoing phase III study called HPV-008 to its original application in the first half of 2009 and a decision by the FDA is expected six months later. The 2007 application now under consideration included only data from an earlier trial